1075. In vitro Activity of Gepotidacin against Escherichia coli Causing Urinary Tract Infections in the United States, Including Molecularly Characterized Fluoroquinolone Resistant Subsets

BACKGROUND: Gepotidacin (GEP) is a novel bacterial type II topoisomerase inhibitor in Phase 3 clinical trials for the treatment of gonorrhea and uncomplicated urinary tract infections (UTI). This study characterized fluoroquinolone (FQ)-not susceptible (not S) E. coli causing UTI in U.S. patients an...

Descripción completa

Detalles Bibliográficos
Autores principales: Mendes, Rodrigo E, Doyle, Timothy B, Arends, S J Ryan, Butler, Deborah, Scangarella-Oman, Nicole, Streit, Jennifer M, Castanheira, Mariana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643800/
http://dx.doi.org/10.1093/ofid/ofab466.1269

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643800/
http://dx.doi.org/10.1093/ofid/ofab466.1269

Ejemplares similares